Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists
Berger T, Zeitlinger M, Popescu V, Magyari M, Airas L, Alkhawajah M, Pugliatti M, Zakaria M, Pozzilli C, Drulovic J, Van Wijmeersch B, Vermersch P, Oreja‐Guevara C. Generics, Biosimilars and Follow‐On Non‐Biologic Complex Drugs for Multiple Sclerosis: A Narrative Review of the Regulatory and Clinical Implications for European Neurologists. European Journal Of Neurology 2025, 32: e70140. PMID: 40231751, PMCID: PMC11998027, DOI: 10.1111/ene.70140.Peer-Reviewed Original ResearchConceptsDisease-modifying treatmentsNon-biological complex drugsImprove patient accessLiterature searchMultiple sclerosisMS careHealthcare systemPatient accessComplex drugsPubMed literature searchSocioeconomic burdenNarrative reviewTolerability profileGlatiramer acetateClinical efficacyClinical studiesEarly onsetEuropean neurologistsClinical implicationsProgressive natureDrugSclerosisOriginal drugPeopleCare
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply